HeartBeam, Inc. (NASDAQ: BEAT) has an average one-year price target of $8.16, with forecasts ranging from a low of $8.08 to a high of $8.40. This target is projected by analysts for August 6, 2026.1
As of February 6, 2026, HeartBeam's common stock was trading at $1.43 per share.2 This suggests a significant potential upside if the company reaches the average analyst price target.
Recent developments for HeartBeam include:
- Analyst Ratings: Firms like Benchmark and Alliance Global Partners have maintained "Speculative Buy" or "Buy" ratings for BEAT throughout 2023 and 2024.1
- FDA Clearances: The company's HeartBeam system recently received U.S. Food and Drug Administration (FDA) clearance for comprehensive arrhythmia assessment. Additionally, a 510(k) application was submitted to the FDA for its 12-lead electrocardiogram (ECG) synthesis software.3
- Public Offering: In February 2025, HeartBeam completed a public offering of common stock at $1.70 per share, raising approximately $10.0 million, with an additional $1.5 million from an over-allotment option. This funding is intended to support key growth milestones and preparation for U.S. commercialization.3
It is important to note that HeartBeam has reported negative earnings per share (TTM) of -0.60 as of August 6, 2025, and negative cash flow from operating activities.4 The stock has also experienced high volatility, with a one-year price change of -59.51% as of August 6, 2025.4
For further in-depth analysis of HeartBeam, including institutional ownership, insider trading, and detailed financial metrics, you can explore the Fintel platform for BEAT (NASDAQ: BEAT).
